InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing

The Hong Kong-traded company will become the latest from the cash-challenged pharma sector to make a second listing on the A-share market Key Takeaways: InnoCare Pharma’s A-share IPO will make it the fourth innovative pharma company with shares traded in Hong Kong and on the mainland’s STAR Market   The company is flush with cash and continues to raise money at every opportunity to finance its R&D By Molly Wen China’s Nasdaq-style STAR Market has become fertile ground for fundraising by innovative yet profit-challenged pharmaceutical companies since its launch in…

Read More »

Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk

Company has changed auditors in a bid to comply with U.S. law and avoid a potential forced delisting from the Nasdaq Key Takeaways: BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law The change could reduce the company’s threat of being forcibly delisted from the Nasdaq By Doug Young It may have listings in Hong Kong and Shanghai, but cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) is making it clear it wants to…

Read More »

FAST NEWS: SEC Names Five Chinese Stocks at Threat of Delisting

The latest: The U.S. Securities and Exchange Commission (SEC) announced Thursday that it has placed five Chinese companies on a list of companies that could face the threat of delisting under the Foreign Company Accountability Act, including BeiGene, Ltd. (BGNE.US; 6160.HK; 688235.SH), Zai Lab Ltd. (ZLAB.US; 9688.HK), Yum China Holdings Inc. (YUMC.US; 9987.HK HK), Hutchmed (China) Ltd. (HCM.US; 0013.HK) and ACM Research Inc. (ACMR:US). Looking up: There are currently more than 270 Chinese stocks listed in the U.S. The SEC has named only five this time, giving the others time…

Read More »

Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat

U.S. securities regulator singles out company for potential delisting, a week after Hutchmed announced its CEO will step down after almost 22 years Key Takeaways U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO Company’s shares have tumbled more than 40% on the developments, even as it reported strong revenue gains for 2021 and nears its first approval to sell a drug in the U.S. By Richard Barbarossa Talk about getting hit when…

Read More »

Zai Lab Revenue Triples, as It Struggles to Break Cycle of Mounting Losses

The biotech company is bringing in bigger sums from its growing stable of drugs approved for sale in China, but is also accelerating its R&D spending Key takeaways: Zai Lab reported its revenue grew 194% last year, but its loss also increased by 162% as it spent heavily on R&D and marketing The company hopes heavy R&D spending can reduce its dependence on licensed products by improving its capacity to innovate By Ken Lo A big revenue jump should be good news for a young biotech company like Zai Lab…

Read More »

New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report

Investors kept a close look at China’s solar and wind power stocks last year, but were least interested in the hobbled education sector By Bamboo Works team Chinese concept stocks experienced unprecedented challenges in the Year of the Ox. The small and mid-sized companies covered by Bamboo Works were no exception, also coming under intense pressure. Looking past their stock prices and financial reports, how did these companies perform in terms of media and investor attention? Which companies stood out despite all the pressures? Our special report highlights such trends…

Read More »

FAST NEWS: BeiGene Shares Plunge on STAR Market Trading Debut

The latest: Biotech company BeiGene Ltd. (BGNE.US; 6160.HK; 688235.SH) on Wednesday announced the completion of its 22.2 billion yuan ($3.5 billion) listing on Shanghai’s STAR Market, becoming the world’s first stock to be simultaneously listed in the U.S., Hong Kong and on one of China’s A-share markets. But the stock performed poorly on its debut on concerns about potential new U.S. sanctions against the company. Looking up: The new listing gives BeiGene new funding to invest in drug research, clinical development and on construction of R&D centers and manufacturing sites.…

Read More »

BeiGene Seeks Historic Third Listing in Shanghai, Complementing US and HK

The 11-year-old money-losing biotech has filed for a listing on Shanghai’s STAR Market to raise more than $3 billion Key Takeaways: BeiGene will become the world’s first stock to be simultaneously listed in the U.S., Hong Kong and on one of China’s A-share markets Some analysts believe that a strong valuation for BeiGene’s new A-share listing could help to boost its stock price in the U.S. and Hong Kong By Jony Ho Biotech firm BeiGene Ltd. (BGNE.US; 6160.HK) will soon become the world’s first stock listed in New York, Hong…

Read More »

I-Mab Gets Boost from Latest Industry Signals on New Cancer Treatment

Company’s shares surged as much as 15% after AstraZeneca unveiled upbeat results for a new class of cancer drugs known as CD73 antibodies Key Takeaways: I-Mab’s shares surged up to 15% on positive results from a peer developing a similar new type of cancer treatment, though they later gave back most of those gains Company has plenty of cash on hand, and could soon get more as it seeks a deal to commercialize the drug, uliledlimab, with a U.S. or European partner By Doug Young It may still be at…

Read More »

Drug Startups Eye Quicker Profits Under China’s New Fast-Track Approvals

Key changes designed to bring cutting-edge drugs more quickly to market have yet to ignite significant rally for money-losing startups Key takeaways: New fast-track approval system could bring cutting-edge drugs to market more quickly Changes could benefit startups with quicker approvals, and by letting them work with big foreign manufacturing partners By Richard Barbarossa A recent regulatory overhaul designed to speed up development and approval of new drugs in China has been welcomed by global pharma giants and local startups alike, aimed at bringing their latest cutting-edge treatments more quickly…

Read More »